Delivery outcome after maternal use of antidepressant drugs in pregnancy: An update using Swedish data

Psychological Medicine

Volumn 40, Issue 10, 2010, Pages 1723-1733

  Reis, M ^a   Kllen B ^b  

^a DEPARTMENT OF FORENSIC GENETICS AND FORENSIC TOXICOLOGY   (Sweden)

^b UNIVERSITY OF LUND   (Sweden)

Author keywords

Antidepressant drugs; congenital malformations; neonatal symptoms; pregnancy

Indexed keywords

ANTIDEPRESSANT AGENT; MONOAMINE OXIDASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; BIRTH WEIGHT; CARDIOVASCULAR MALFORMATION; CHEMICALLY INDUCED DISORDER; CONFIDENCE INTERVAL; CONGENITAL MALFORMATION; DRUG EFFECT; FEMALE; GESTATIONAL AGE; HUMAN; HYPOSPADIAS; MALE; MATERNAL AGE; NEWBORN; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PSYCHOLOGICAL ASPECT; REGISTER; RISK; SWEDEN;

ABNORMALITIES, DRUG-INDUCED; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BIRTH WEIGHT; CARDIOVASCULAR ABNORMALITIES; CONFIDENCE INTERVALS; FEMALE; GESTATIONAL AGE; HUMANS; HYPOSPADIAS; INFANT, NEWBORN; MALE; MATERNAL AGE; MONOAMINE OXIDASE INHIBITORS; ODDS RATIO; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; REGISTRIES; SEROTONIN UPTAKE INHIBITORS; SWEDEN;

EID: 77957168545     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291709992194     Document Type: Article

References (48)

1. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM (2007). Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. New England Journal of Medicine 356, 2684-2692.
2. Andrade SE, McPhillips H, Loren D, Raebel MA, Lane K, Livingston J, Boudreau DM, Smith DH, Davis RL, Willy ME, Platt R (2009). Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiology and Drug Safety 18, 246-252.
3. Bar-Oz B, Einarson T, Einarson A, Boskovic R, O'Brien L, Malm H, Berard A, Koren G (2007). Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. Clinical Therapeutics 29, 918-926.
4. Berard A, Ramos E, Rey E, Blais L, St-Andre M, Oraichi D (2007). First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Research. Part B, Developmental and Reproductive Toxicology 80, 18-27.
5. Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, Mitchell AA (2006). Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. New England Journal of Medicine 354, 579-587. (Pubitemid 43209105)
6. Chung TK, Lau TK, Yip AS, Chiu HF, Lee DT (2001). Antepartum depressive symptomatology is associated with adverse obstetric and neonatal outcomes. Psychosomatic Medicine 63, 830-834.
7. Cole JA, Ephross SA, Cosmatos IS, Walker AM (2007). Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiology and Drug Safety 16, 1075-1085.
8. Costei AM, Kozer E, Ho T, Ito S, Koren G (2002). Perinatal outcome following third trimester exposure to paroxetine. Archives of Pediatrics and Adolescent Medicine 156, 1129-1132.
9. Davis RL, Rubanowice D, McPhillips H, Raebel MA, Andrade SE, Smith D, Yood MU, Platt R (2007). Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiology and Drug Safety 16, 1086-1094.
10. Dayan J, Creveuil C, Herlicoviez M, Herbel C, Baranger E, Savoye C, Thouin A (2002). Role of anxiety and depression in the onset of spontaneous preterm labor. American Journal ofEpidemiology 155, 293-301.
11. Dayan J, Creveuil C, Marks MN, Conroy S, Herlicoviez M, Dreyfus M, Tordjman S (2006). Prenatal depression, prenatal anxiety, and spontaneous preterm birth: a prospective cohort study among women with early and regular care. Psychosomatic Medicine 68, 938-946.
12. Diav-Citrin O, Shechtman S, Weinbaum D, Arnon J, Di Gianantonio E, Clementi M, Ornoy A (2005). Paroxetine and fluoxetine in pregnancy: a multicenter, prospective, controlled study. Reproductive Toxicology 20, 459.
13. Diav-Citrin O, Shechtman S, Weinbaum D, Wajnberg R, Avgil M, Di Gianantonio E, Clementi M, Weber-Schoendorfer C, Schaefer C, Ornoy A (2008). Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. British Journal of Clinical Pharmacology 66, 695-705.
14. Dubnov-Raz G, Juurlink DN, Fogelman R, Merlob P, Ito S, Koren G, Finkelstein Y (2008). Antenatal use of selective serotonin-reuptake inhibitors and QT interval prolongation in newborns. Pediatrics 122, e710-e715.
15. Einarson TR, Einarson A (2005). Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiology and Drug Safety 14, 823-827.
16. Ericson A, Kallen B, Wiholm B (1999). Delivery outcome after the use of antidepressants in early pregnancy. European Journal of Clinical Pharmacology 55, 503-508. (Pubitemid 29446550)
17. Hallberg P, Sjoblom V (2005). The use of selective serotonin reuptake inhibitors during pregnancy and breast-feeding: a review and clinical aspects. Journal of Clinical Psychopharmacology 25, 59-73.
18. Hines RN, Adams J, Buck GM, Faber W, Holson JF, Jacobson SW, Keszler M, McMartin K, Segraves RT, Singer LT, Sipes IG, Williams PL (2004). NTP-CERHR Expert Panel Report on the reproductive and developmental toxicity of fluoxetine. Birth Defects Research. Part B, Developmental and Reproductive Toxicology 71, 193-280.
19. Kallen B (1995). A birth weight for gestational age standard based on data in the Swedish Medical Birth Registry, 1985-1989. European Journal of Epidemiology 11, 601-606.
20. Kallen B (2004). Neonate characteristics after maternal use of antidepressants in late pregnancy. Archives of Pediatrics and Adolescent Medicine 158, 312-316.
21. Kallen B (2005). Methodological issues in the epidemiological study of the teratogenicity of drugs. Congenital Anomalies 45, 44-51.
22. Kallen B (2007). The safety of antidepressant drugs during pregnancy. Expert Opinion on Drug Safety 6, 357-370.
23. Kallen B (2008). Drug treatment for depression during pregnancy. In New Perspectives on Women and Depression (ed. W. Hansson and E. Olsson), pp. 87-108. Nova Science Publishers: USA.
24. Kallen B, Otterblad Olausson P (2003). Maternal drug use in early pregnancy and infant cardiovascular defect. Reproductive Toxicology 17, 255-261.
25. Kallen B, Otterblad Olausson P (2006). Antidepressant drugs during pregnancy and infant congenital heart defect. Reproductive Toxicology 21, 221-222.
26. Kallen B, Otterblad Olausson P (2007). Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Research. Part A, Clinical and Molecular Teratology 79, 301-308.
27. Kallen B, Otterblad Olausson P (2008). Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiology and Drug Safety 17, 801-806.
28. Levinson-Castiel R, Merlob P, Linder N, Sirota L, Klinger G (2006). Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Archives of Pediatrics and Adolescent Medicine 160, 173-176.
29. Li D, Liu L, Odouli R (2009). Presence of depressive symptoms during early pregnancy and the risk of preterm delivery: a prospective cohort study. Human Reproduction 24, 146-153.
30. Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA (2007). First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. New England Journal of Medicine 356, 2675-2683.
31. Lund N, Pedersen LH, Henriksen TB (2009). Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Archives of Pediatrics and Adolescent Medicine 163, 949-954.
32. Malm H, Klaukka T, Neuvonen PJ (2005). Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstetrics and Gynecology 106, 1289-1296.
33. McElhatton PR, Garbis HM, Elefant E, Vial T, Bellemin B, Mastroiacovo P, Arnon J, Rodriguez-Pinilla E, Schaefer C, Pexieder T, Merlob P, Dal Verme S (1996). The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European Network of Teratology Information Services (ENTIS). Reproductive Toxicology 10, 285-294.
34. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C (2006). Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Archives of General Psychiatry 63, 898-906.
35. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C (2008a). Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study. British Journal of Psychiatry 192, 338-343.
36. Oberlander TF, Warburton W, Misri S, Riggs W, Aghajanian J, Hertzman C (2008 b). Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Research. Part B, Developmental and Reproductive Toxicology 83, 68-76.
37. Orr ST, James SA, Blackmore Prince C (2002). Maternal prenatal depressive symptoms and spontaneous preterm births among African-American women in Baltimore, Maryland. American Journal of Epidemiology 156, 797-802.
38. Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH (2009). Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. British Medical Journal 339, b3569.
39. Potts AL, Young KL, Carter BS, Shenai JP (2007). Necrotizing enterocolitis associated with in utero and breast milk exposure to the selective serotonin reuptake inhibitor, escitalopram. Journal ofPerinatology 27, 120-122.
40. Sanz EJ, De-las-Cuevas C, Kiuru A, Bate A, Edwards R (2005). Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 365, 482-487.
41. Simon GE, Cunningham ML, Davis RL (2002). Outcomes of prenatal antidepressant exposure. American Journal of Psychiatry 159, 2055-2061.
42. Stiskal JA, Kulin N, Koren G, Ho T, Ito S (2001). Neonatal paroxetine withdrawal syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition 84, F134-F135.
43. Suri R, Altshuler L, Hellemann G, Burt VK, Aquino A, Mintz J (2007). Effects of antenatal depression and antidepressant treatment on gestational age at birth and isk of preterm birth. American Journal of Psychiatry 164, 1206-1213.
44. Toh S, Mitchell AA, Louik C, Werler MM, Chambers CD, Hernandez-Diaz S (2009). Selective serotonin reuptake inhibitor use and risk of gestational hypertension. American Journal of Psychiatry 166, 320-328.
45. Treichel M, Schwendener Scholl K, Kessler U, Joeris A, Nelle M (2009). Is there a correlation between venlafaxine therapy during pregnancy and a higher incidence of necrotizing enterocolitis? World Journal of Pediatrics 5, 65-67.
46. Wichman CL, Moore KM, Lang TR, St Sauver JL, Heise Jr. RH, Watson WJ (2009). Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clinic Proceedings 84, 23-27.
47. Wisner KL, Sit DK, Hanusa BH, Moses-Kolko EL, Bogen DL, Hunker DF, Perel JM, Jones-Ivy S, Bodnar LM, Singer LT (2009). Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. American Journal of Psychiatry 166, 557-566.
48. Wogelius P, Norgaard M, Gislum M, Pedersen L, Munk E, Mortensen PB, Lipworth L, Sorensen HT (2006). Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 17, 701-704.